Back to discover
Drug

Lysine

In clinical development
Emerging researchEarly-to-mid developmentRising momentum
Also known as (S)-lysine, 6-ammonio-L-norleucine, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free+45 more

(S)-lysine, 6-ammonio-L-norleucine, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Clinisol 15, Freamine III 10, Hepatamine 8, Hepatasol, L-Formula, L-Lysin, L-Lysine, L-lys, LYS, Lysine acid, Nephramine, Plenamine, PremaSol, ProSol, ProcalAmine 3, Travasol 10, Travasol 10%, Trophamine, Trophamine 10 %, Trophamine 6 %, Lysina, (S)-2,6-diaminohexanoic acid, Clinimix 4.25/10, Clinimix 4.25/25, Clinimix 4.25/5, Clinimix 5/15, Clinimix 5/20, Clinimix 5/25, Clinimix E 2.75/5, Clinimix E 4.25/10, Clinimix E 4.25/5, Clinimix E 5/15, Clinimix E 5/20, Clinimix E 5/25, L-2,6-Diaminocaproic acid, Lysinum.

7
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Leucine as a Probe of Kynurenine-Induced Glutamate and Neural Circuit Dysfunction in Midlife Depression

Clinical trial2025-04-24Results expected Q2 2028 · ClinicalTrials.gov

Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3

Clinical trial2024-06-05Results posted · ClinicalTrials.gov

Histone lactylation: from tumor lactate metabolism to epigenetic regulation.

Research2024-03-03International journal of biological sciences

The Effect of Acute Lysine Administration on α-aminoadipic Acid

Clinical trial2016-10-01Completed · ClinicalTrials.gov

Hippocampal CA1 interneurons: an in vivo intracellular labeling study.

Research1995-10-01The Journal of neuroscience : the official journal of the Society for Neuroscience

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Lysine
Aliases & brands
(S)-lysine6-ammonio-L-norleucineAminosyn 10%, Sulfite-FreeAminosyn 3.5 % M, Sulfite FreeAminosyn 8.5 % with Electrolytes, Sulfite-FreeAminosyn 8.5%, Sulfite-FreeAminosyn II 10 %Aminosyn II 15%Aminosyn II 8.5 % with Electrolytes, Sulfite-FreeAminosyn II 8.5 %, Sulfite-FreeAminosyn-HBC 7 %, Sulfite-FreeAminosyn-PF 10 %, Sulfite-FreeAminosyn-PF 7%Clinisol 15Freamine III 10Hepatamine 8HepatasolL-FormulaL-LysinL-LysineL-lysLYSLysine acidNephraminePlenaminePremaSolProSolProcalAmine 3Travasol 10Travasol 10%TrophamineTrophamine 10 %Trophamine 6 %Lysina(S)-2,6-diaminohexanoic acidClinimix 4.25/10Clinimix 4.25/25Clinimix 4.25/5Clinimix 5/15Clinimix 5/20Clinimix 5/25Clinimix E 2.75/5Clinimix E 4.25/10Clinimix E 4.25/5Clinimix E 5/15Clinimix E 5/20Clinimix E 5/25L-2,6-Diaminocaproic acidLysinum
RxNorm CUI
6536
ChEMBL ID
CHEMBL8085
ATC codes
B05XB03
UNII
K3Z4F929H6

Clinical trials

5 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
5
registered trials across all phases
LATEST COMPLETION 2023
1
Active studies
1
Recruiting
2
Late-stage (III+)
4
Completed
PHASE DISTRIBUTIONn = 5
Phase 12Phase 21Phase N / A2

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

7 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19952024
Most influential
Recent papers
Major research themes8
Histones2Bacillota1Colitis1Colorectal Neoplasms1Homocysteine1Kynurenine1Neoplasms1Parkinson Disease1
Journals, researchers & institutions
Top journals
  • Aging cell1
  • Autophagy1
  • International journal of biological sciences1
  • Nature1
  • Nature communications1
  • The Journal of neuroscience : the official journal of the Society for Neuroscience1
Leading researchers
  • Shi S2
  • Zhang Z2
  • Alfiler L1
  • Alva AS1
  • Anastassiou C1
  • Arkhipov A1
  • Baker K1
  • Bakken TE1
Leading institutions
free-text, unnormalised
  • Allen Institute for Brain Science1
  • Brigham and Women's Hospital/Dana-Farber Cancer Institute1
  • Cancer Center Amsterdam1
  • Center for Molecular and Behavioral Neuroscience1
  • Center for Neurogenomics and Cognitive Research (CNCR)1
  • CHU de Quebec and Laval University1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 2 of the same disease areas as Lysine in the shared literature.

2 shared diseases1 shared paper

Studied across 2 of the same disease areas as Lysine in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials